Biomarker testing patterns and use of targeted therapy in Medicare Fee-for-Service (FFS) beneficiaries newly diagnosed with metastatic non-small cell lung cancer (mNSCLC).

被引：0
|
作者：
Patel, Anik
Jamotte, Aurelien
Matsuda, Tara
Das, Partha Manas
Elkhouly, Ehab
Xi, Ann
Jones, Barton
Murunga, Anne
Petrilla, Allison
Markward, Nathan
Stevinson, Kendall Lee
机构：
[1] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA USA
[2] Amgen Europ, Econ Modeling CoE PACE, Rotkreuz, Switzerland
[3] Amgen Inc, US Med, Thousand Oaks, CA USA
[4] Amgen Inc, Global Med, Thousand Oaks, CA USA
[5] Avalere Hlth, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 29期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
278
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Medical cost of care by line of treatment (LoT) in Medicare Fee-for-Service (FFS) beneficiaries with KRAS-mutated metastatic non-small cell lung cancer (mNSCLC).
    Matsuda, Tara
    Jamotte, Aurelien
    Xi, Ann
    Jones, Barton
    Petrilla, Allison
    Markward, Nathan
    Murunga, Anne
    Stevinson, Kendall Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [2] Real-world patterns of biomarker testing and targeted therapy in metastatic non-small cell lung cancer (mNSCLC) in the community oncology setting.
    Nadler, Eric S.
    Vasudevan, Anupama
    Davies, Kalatu
    Wang, Yunfei
    Gupta, Ravindra
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Predictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
    Robert, Nicholas J.
    Chen, Liwei
    Espirito, Janet L.
    Karhade, Mandar
    Evangelist, Makenzi Colleen
    Neubauer, Marcus A.
    Bullock, Susie A.
    Walberg, Jennifer M.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Real-world analysis of biomarker testing and use of targeted therapies in metastatic non-small cell lung cancer (mNSCLC) in the United States (US)
    Dennis, Michael J.
    Abrahami, Devin
    Vieira, Maria Cecilia
    Benjumea, Darrin
    Boyd, Marley
    Shao, Anran
    Duncan, Kirsten
    Kelton, John
    Patel, Sandip P.
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Trends in treatment patterns among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer
    Dieguez, G.
    Tomicki, S.
    DeStephano, D.
    Cockrum, P.
    Kim, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1091 - S1092
  • [6] TRENDS OF GENETIC TESTING PATTERNS, SURVIVAL, AND MEDICAL COSTS OF INDIVIDUALS NEWLY DIAGNOSED WITH METASTATIC NON-SMALL CELL LUNG CANCER
    Cheng, J. S.
    Hsu, J. Y.
    Ku, H. P.
    VALUE IN HEALTH, 2023, 26 (06) : S252 - S252
  • [7] Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma
    Shah, Anne
    Petrilla, Allison
    Rebeira, Mayvis
    Feliciano, Joseph
    LeBlanc, Thomas W.
    Lisano, Julie
    BLOOD, 2019, 134
  • [8] TOTAL COST OF CARE AND OUT-OF-POCKET SPENDING FOR MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH ADVANCED MELANOMA, ADVANCED RENAL CELL CARCINOMA, OR ADVANCED NON-SMALL CELL LUNG CANCER
    Schwartz, T.
    Morley, M.
    Lane, D.
    Palaia, J.
    Macher, D.
    Petrilla, A.
    VALUE IN HEALTH, 2022, 25 (07) : S352 - S352
  • [9] Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service
    Karunanithi, Vijayalakshmi
    Win, Thida
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [10] Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer
    Reckamp, Karen L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05): : 601 - 604
12345